Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Avenue Therapeutics, Inc. (ATXI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4100-0.0500 (-3.42%)
At close: 01:00PM EST
1.4400 +0.03 (+2.13%)
After hours: 04:55PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.4600
Open1.4600
Bid1.3900 x 1100
Ask1.4400 x 2200
Day's Range1.3715 - 1.5099
52 Week Range1.3600 - 26.8500
Volume168,782
Avg. Volume4,473,649
Market Cap6.739M
Beta (5Y Monthly)-0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATXI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avenue Therapeutics, Inc.
    CARA: Rating increased to a HOLDCARA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported financial results and recent corporate highlights for the third quarter ended September 30, 2022. “I am pleased that Avenue has achieved important financial milestones providing a path to continue developing drug

  • Benzinga

    Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

    Avenue Therapeutics Inc (NASDAQ: ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ: FBIO). Founded in December 2019, Baergic Bio focuses on developing a pharmaceutical product for CNS disorders. Its pipeline currently includes a single compound, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator, which was in-licensed from AstraZeneca Plc (NASDAQ: AZN).

  • GlobeNewswire

    Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

    NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“CNS”) diseases, today announced the closing of the acquisition of Baergic Bio, Inc. (“Baergic Bio”) pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech, Inc. Founded in December 2019, Bae

Advertisement
Advertisement